Literature DB >> 2460394

Endoscopic management of malignant biliary obstruction: stents of 10 French gauge are preferable to stents of 8 French gauge.

A G Speer1, P B Cotton, K D MacRae.   

Abstract

To assess whether the use of large stents is justified, we have retrospectively reviewed the results of 8 French gauge (FG) stents with pigtails and 10 FG straight stents in the palliation of biliary obstruction due to malignancy. The incidence of cholangitis following stent insertion was significantly lower with 10 FG stents, 3 (5%), compared with 8 FG stents, 13 (34%), p less than 0.001, chi 2. Stent survival until blockage was significantly longer for 10 FG (median 32 weeks) compared with 8 FG (median 12 weeks), p less than 0.001, log-rank. The superior performance of the 10 FG stents was due to their larger diameter which gives them a flow capacity much greater than the physiological bile flow. We recommend that stents of at least 10 FG diameter are used for the endoscopic palliation of biliary obstruction due to malignancy.

Entities:  

Mesh:

Year:  1988        PMID: 2460394     DOI: 10.1016/s0016-5107(88)71407-8

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  45 in total

Review 1.  Plastic biliary stent occlusion: factors involved and possible preventive approaches.

Authors:  Gianfranco Donelli; Emilio Guaglianone; Roberta Di Rosa; Fausto Fiocca; Antonio Basoli
Journal:  Clin Med Res       Date:  2007-03

Review 2.  Antireflux biliary stents: are they the solution to stent occlusions?

Authors:  D Nageshwar Reddy; Rupa Banerjee; Ong Wai Choung
Journal:  Curr Gastroenterol Rep       Date:  2006-04

3.  Clogging of biliary endoprostheses: a new perspective.

Authors:  P P Coene; A K Groen; J Cheng; M M Out; G N Tytgat; K Huibregtse
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

Review 4.  Endoscopic stenting for palliation of malignant biliary obstruction. A review of progress in the last 15 years.

Authors:  J J Sung; S C Chung
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

5.  Laparoscopic biliary and gastric bypass: a useful adjunct in the treatment of carcinoma of the pancreas.

Authors:  M Rhodes; L Nathanson; G Fielding
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

6.  Multicenter study evaluating factors for stent patency in patients with malignant biliary strictures: development of a simple score model.

Authors:  Petra G A van Boeckel; Ewout W Steyerberg; Frank P Vleggaar; Marcel J M Groenen; Ben J M Witteman; Bas L A M Weusten; Han Geldof; Adriaan C I T L Tan; Marina J A L Grubben; Jan Nicolai; Peter D Siersema
Journal:  J Gastroenterol       Date:  2011-07-14       Impact factor: 7.527

7.  Technical feasibility and revision efficacy of the sequential deployment of endoscopic bilateral side-by-side metal stents for malignant hilar biliary strictures: a multicenter prospective study.

Authors:  Tae Hoon Lee; Do Hyun Park; Sang Soo Lee; Hyun Jong Choi; Jun Kyu Lee; Tae Hyeon Kim; Jong Hyeok Kim; Seok Jeong; Sang-Heum Park; Jong Ho Moon
Journal:  Dig Dis Sci       Date:  2012-08-11       Impact factor: 3.199

8.  A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction.

Authors:  H Isayama; Y Komatsu; T Tsujino; N Sasahira; K Hirano; N Toda; Y Nakai; N Yamamoto; M Tada; H Yoshida; Y Shiratori; T Kawabe; M Omata
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.

Authors:  Angela Lamarca; Christina Rigby; Mairéad G McNamara; Richard A Hubner; Juan W Valle
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 10.  Plastic or metal stents for benign extrahepatic biliary strictures: a systematic review.

Authors:  Petra G A van Boeckel; Frank P Vleggaar; Peter D Siersema
Journal:  BMC Gastroenterol       Date:  2009-12-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.